The first upper lid sagging treatment! FDA approves Upneeq (hydroxymetalyniahydrophine hydroxalysis hydrochloride eye drops)!

upper lid sagging (Photo: medscape.com)July 10, 2020 /bio-valleyBIOON/ -- Osmotica Pharmaceuticals recently announced that the U.SFood and Drug Administration (
FDA) has approved Upneeq (hydroxymetformin odythed eye drops, 0.1 percent), RVL-1201), a new treatment for the drooping of the upper lidThe sagging of the upper eyelids is a disease characterized by abnormal sagging of the upper lids, which limits the field of visionit's worth noting thatUpneeq is the only drug approved by theFDA to treat sagging upper lidsapproval marks a milestone in the provision of Upneeq to provide ophthalmology specialists with a safe and convenient non-surgical option to treat patients with sagging upper lidsthe safety and efficacy of the drug and the ease of administration once a day will provide an important innovation in ophthalmologyAs there was no previously approved treatment, upper lid sagging was often underestimated or ignoredUpneeq has the potential to address important unmet needs in upper lid sagging treatmentUpneeq's therapeutic effects (before the drop, 6h after the drop)millions of people in the United States alone suffer from sagging upper lids; A study involving adults over 50 found that the prevalence of sagging upper lids was about 11.5 percent among adults over 50Upneeq is a safe, effective and pioneering treatment for the sagging of the acquired upper lidThe drooping of the acquired upper lid is usually caused by partial or complete dysfunction of the M?ller muscle, which together with the upper lid lift isophyle lifts the eyelidsin two key double-blind efficacy studies, the Upneeq treatment group showed statistically significant improvements compared to the placebo group, using the Lester Peripheral Field OfSight Trial (LPFT) and eyelid lift (measured by MRD-1 with the edge reflection distance test)A third critical safety study successfully showed that Upneeq was dispensed every morning (in both eyes) for 12 weeks and was well toleratedMost adverse events are mild and self-limiting(BioValleyBioon.com)original origins:Osmotica Pharmaceuticals plc s Receives FDA for Upneeq ™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelids) in Adult